Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (TRDA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TRDA · as of Sep 30, 2025
Ownership Breakdown
118
Institutional Holders
▲ 11 vs Q2
$168.67M
Total Inst. Value
▼ $30.12M vs Q2
38.82M
Shares Outstanding
freeFloat 50.22%
28.48M
13F Shares Held
▼ 1.11M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TRDA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP pharmaceutical preparations | 4.87M | 11.77% | 11.77% | $28.22B | Nov 14, 2025 | — held |
MPM ASSET MANAGEMENT LLC pharmaceutical preparations | 4.38M | 10.60% | 10.60% | $25.41B | Nov 14, 2025 | — held |
5AM VENTURE MANAGEMENT, LLC pharmaceutical preparations | 4.26M | 10.30% | 10.30% | $24.69B | Nov 14, 2025 | ▼ 52.0K |
BLACKROCK, INC. pharmaceutical preparations | 2.04M | 4.94% | 4.94% | $11.86B | Nov 12, 2025 | ▲ 21.9K |
VANGUARD GROUP INC pharmaceutical preparations | 1.60M | 3.88% | 3.88% | $9.30B | Nov 7, 2025 | ▼ 635 |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 954.4K | 2.31% | 2.31% | $5.54B | Nov 14, 2025 | ▼ 106.3K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 836.6K | 2.02% | 2.02% | $4.85B | Nov 14, 2025 | ▲ 666.3K |
STEPSTONE GROUP LP pharmaceutical preparations | 761.3K | 1.84% | 1.84% | $4.42B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 645.1K | 1.56% | 1.56% | $3.74B | Nov 12, 2025 | ▲ 13.6K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 594.3K | 1.44% | 1.44% | $3.45B | Nov 13, 2025 | ▲ 214.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+2.95M shares10
New Positions
first time holders7
Decreased
−2.46M shares0
Sold Out
fully exitedNet shares change (top 50)
+486.9K
+2.95M / −2.46M
Net new holders
+29
10 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TRDA insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
4
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Zeiher Bernhardt G director | May 20, 2026 | Purchase | 5,000 | $5.86 | $29.3K | 5.0K | Form 4 ↗ |
Sethuraman Natarajan President, Research & Develop. | May 4, 2026 | Sale | 25,907 | $15.39 | $398.8K | 216.3K | Form 4 ↗ |
Dowden Nathan J President & COO | May 4, 2026 | Sale | 15,000 | $15.33 | $230.0K | 198.6K | Form 4 ↗ |
WENTWORTH KORY JAMES Chief Financial Officer | Apr 1, 2026 | Sale | 2,500 | $12.95 | $32.4K | 119.0K | Form 4 ↗ |
Dowden Nathan J President & COO | Mar 9, 2026 | Sale | 3,116 | $13.02 | $40.6K | 210.5K | Form 4 ↗ |
Dowden Nathan J President & COO | Mar 10, 2026 | Sale | 11,894 | $13.05 | $155.2K | 198.6K | Form 4 ↗ |
WENTWORTH KORY JAMES Chief Financial Officer | Mar 9, 2026 | Sale | 5,089 | $13.00 | $66.2K | 132.9K | Form 4 ↗ |
WENTWORTH KORY JAMES Chief Financial Officer | Mar 10, 2026 | Sale | 11,388 | $13.02 | $148.2K | 121.5K | Form 4 ↗ |
WENTWORTH KORY JAMES Chief Financial Officer | Mar 4, 2026 | Sale | 7,988 | $12.25 | $97.9K | 138.0K | Form 4 ↗ |
Doshi Dipal CEO | Mar 1, 2026 | Award | 139,400 | — | — | 555.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Entrada Therapeutics, Inc. (TRDA) is primarily owned by institutional investors, who hold approximately 73.3% of total shares outstanding. Company insiders own approximately 49.78%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Entrada Therapeutics, Inc. is BAKER BROS. ADVISORS LP, holding approximately 4.87 million shares — equal to 11.77% of outstanding shares — as of September 30, 2025.
A total of 118 institutional investors currently hold TRDA stock, with a combined institutional value of approximately $168,671,706 as of the most recent 13F filing period.
Frequently asked questions
TRDA ownershipEntrada Therapeutics, Inc. (TRDA) is primarily owned by institutional investors, who hold approximately 73.3% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 11.77% stake. Company insiders hold 49.78%. Data sourced from SEC Form 13F as of September 30, 2025.